Recently,
Japanese experts have investigated the positive effects of the diabetes drug
dapagliflozin on heart failure patients.
Heart failure is a condition in which the
heart is unable to pump bloodaround the body properly. dapagliflozin heart failure patient information leaflet
The Japanese experts focused the
research on how the aforementioned drug affects the test of a specific biomarker
UACR (urine albumin to creatinine
ratio) in the urine. The research was led by Dr. Fumiki Yoshihara at the National
Cerebral and Cardiovascular Center in Osaka, Japan. The researchers wanted to
see if dapagliflozin could improve UACR levels in patients with heart failure
and type 2 diabetes.
The study included
146 patients who were given 5 mg of dapagliflozin daily for 2 years. The
researchers found that the drug had no significant effect on UACR, but that the
drug was helpful in some heart-related problems.
The drug reduced the
volume of the left ventricle of the heart. Because left ventricular enlargement
can be a problem in terms of heart failure. In addition, patients also
experienced fewer serious cardiac events, such as the need to go to the
hospital in an emergency.
